Altered Innate Immune Responses in Neutrophils from Patients with Well- and Suboptimally Controlled Asthma
Table 2
Smoking history and inhaled corticosteroid (ICS) use of healthy controls and asthmatics.
(a)
Healthy controls
Age
Sex
Smoking status
Pack years
66
Male
Nonsmoker
0
66
Male
Nonsmoker
0
62
Female
Ex-smoker
15
70
Male
Nonsmoker
0
63
Female
Nonsmoker
0
67
Male
Nonsmoker
0
61
Female
Nonsmoker
0
67
Male
Nonsmoker
0
20
Male
Nonsmoker
0
(b)
Asthma, well-controlled
Age
Sex
Smoking status
Pack years
Daily ICS BDP-HFA equivalent (μg/day)
ICS in last 12 months in BDP-HFA equivalent (μg/day)
69
Female
Nonsmoker
0
0
200 (during exacerbations)
71
Male
Ex-smoker
18
200
—
75
Male
Nonsmoker
0
0
—
63
Male
Ex-smoker
0.5
1000
2000 (when needed)
52
Male
Nonsmoker
0
0
(exercise only)
61
Female
Nonsmoker
0
0
200 (in the last 12 months, ceased 3 months ago)
63
Male
Current smoker
43
0
200 (in high humidity, not used in the past months)
73
Male
Ex-smoker
21
1000
—
28
Male
Nonsmoker
0
125
—
69
Female
Nonsmoker
0
(when sick)
65
Female
Nonsmoker
0
250
500 (when sick)
(c)
Asthma, suboptimally controlled
Age
Sex
Smoking status
Pack years
Daily ICS BDP-HFA equivalent (μg/day)
Oral steroid use in last 12 months
62
Male
Ex-smoker
0.2
800
Yes
71
Female
Ex-smoker
0.6
400
Yes
74
Male
Ex-smoker
4.5
1000
No
47
Male
Nonsmoker
0
1000
No
73
Female
Nonsmoker
0
1000
Yes
52
Male
Ex-smoker
7.15
200
No
59
Male
Nonsmoker
0
500
No
See Section 2 for inclusion criteria. ICS-only inhaler; all other patients using ICS/LABA consistent with Australian prescribing trends [37]. BDP-HFA: beclometasone dipropionate (hydrofluoroalkane propellant). ICS: inhaled corticosteroid.
